Dynamics of prevalence of autosomal dominant polycystic kidney disease in patients receiving renal replacement therapy in the Republic of Tajikistan
- Authors: Jalilzoda S.S.1, Yesayan A.M.1, Ali-Zade S.G.2, Murodzoda A.M.3, Saymukhidinov M.M.4, Tursunzoda R.A.5
-
Affiliations:
- Pavlov First Saint Petersburg State Medical University
- Tajik State Medical University named after Abuali Ibni Sino
- Institute of Postgraduate Education in Healthcare of the Republic of Tajikistan
- National Scientific Center for Human Organ and Tissue Transplantation
- Tajik Research Institute of Preventive Medicine
- Issue: Vol 17, No 4 (2025)
- Pages: 45-50
- Section: Original Articles
- URL: https://journals.rcsi.science/2075-3594/article/view/375410
- DOI: https://doi.org/10.18565/nephrology.2025.4.45-50
- ID: 375410
Cite item
Open Access
Access granted
Subscription Access
Abstract
Objective. Analysis of the dynamics of the number of patients with autosomal dominant polycystic kidney disease (ADPKD) receiving renal replacement therapy (hemodialysis or kidney transplantation) in the Republic of Tajikistan.
Materials and methods. The dynamics of the number of patients with ADPKD receiving renal replacement therapy (RRT) in the Republic of Tajikistan from 2018 to 2024, demographic characteristics, the structure of etiologic factors of stage 5 chronic kidney disease (CKD C5), RRT methods (HD and KT), and the dynamics of the number of patients who underwent KT were studied.
Results. The number of patients with polycystic kidney disease on HD increased from 7 in 2018 to 12 in 2024, corresponding to an average annual increase of 0.83 patients and a significant upward trend (r = 0.86; p = 0.012). This increase is small in absolute numbers, but significant in relative terms (70% over 7 years). Despite fluctuations in individual years, the trend line is ascending (R²=0.74), indicating a gradual expansion of the cohort of patients with ARPKD receiving dialysis treatment. The main causes of end-stage renal disease were: chronic glomerulonephritis (56.7%), diabetic kidney disease (32.1%), chronic pyelonephritis (4.7%), urolithiasis (3.8%), ADPKD (1.1%), congenital kidney/urinary tract anomalies (0.9%), and systemic vasculitis (0.7%). Patients with polycystic kidney disease accounted for only 1.1% of the dialysis population. Despite the small proportion of ADPKD among dialysis patients, the transplant program in Tajikistan began to cover these patients as well. In 2020–2024. A total of 33 donor kidney allotransplantations were performed in patients with ADPKD, accounting for 5% of the total number of transplants performed during the same period.
Conclusion. During the study period, a clear increase in the number of patients with ADPKD requiring RRT (primarily HD) was observed, indicating improved disease detection and expanded access to dialysis. The practical conclusion of the study is a recommendation to develop related kidney transplantation for patients with ADPKD, as transplantation provides them with improved survival and quality of life.
About the authors
Safarkhon S. Jalilzoda
Pavlov First Saint Petersburg State Medical University
Author for correspondence.
Email: sino_doctor@mail.ru
ORCID iD: 0009-0005-4446-0249
Department of Nephrology and Dialysis, Cand.Sci. (Med.), Doctoral Candidate
Russian Federation, Saint PetersburgAshot M. Yesayan
Pavlov First Saint Petersburg State Medical University
Email: essaian.ashot@gmail.com
ORCID iD: 0000-0002-7202-3151
Dr.Sci. (Med.), Professor, Chief External Expert in Nephrology of the Northwestern Federal District of the Russian Federation, Head of the Department of Nephrology and Dialysis
Russian Federation, Saint PetersburgSukhrob G. Ali-Zade
Tajik State Medical University named after Abuali Ibni Sino
Email: suhrob_a@mail.ru
ORCID iD: 0000-0002-2456-7509
Cand.Sci. (Med.), Associate Professor, Department of Surgical Diseases No. 1 named after Academician K.M. Kurbonov
Tajikistan, DushanbeAlisher M. Murodzoda
Institute of Postgraduate Education in Healthcare of the Republic of Tajikistan
Email: Alishermuradov@mail.ru
Dr.Sci. (Med.), Professor, Head of the Department of Efferent Medicine and Intensive Care
Tajikistan, DushanbeMakhmadsafar M. Saymukhidinov
National Scientific Center for Human Organ and Tissue Transplantation
Email: msaymukhidinov@mail.ru
Head of the Kidney and Pancreas Transplantation Department
Tajikistan, DushanbeRustam A. Tursunzoda
Tajik Research Institute of Preventive Medicine
Email: trustam.art@mail.ru
ORCID iD: 0000-0002-5518-6258
Cand.Sci. (Med.), Senior Researcher
Tajikistan, DushanbeReferences
- Bergmann C., Guay-Woodford L.M., Harris P.C. et al. Polycystic kidney disease. Nat. Rev. Dis. Primers. 2018;4(1):1–19. doi: 10.1038/s41572-018-0047-y.
- Cornec-Le Gall E., Alam A., Perrone R.D Autosomal dominant polycystic kidney disease. Lancet. 2019;393(10174):919–35. Doi: 10.1016/ S0140-6736(19)30447-9.
- Gimpel C., Bergmann C., Bockenhauer D. et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat. Rev. Nephrol. 2019;15(11):713–26. doi: 10.1038/s41581-019-0155-2.
- Liyanage T., Ninomiya T., Jha V. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–82. doi: 10.1016/S0140-6736(14)61601-9.
- Prikhodina L., Komissarov K., Bulanov N. et al. Regional Board and ISN-GKHA Team Authors. Capacity for the management of kidney failure in the International Society of Nephrology Newly Independent States and Russia region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney Int. Suppl. (2011). 2024;13(1):71–82. doi: 10.1016/j.kisu.2024.01.005.
- Amouzegar A., Asanbek Kyzy A., Cho Y. et al. Capacity for the management of kidney failure in the ISN Newly Independent States and Russia region: 2023 ISN-GKHA report. Kidney Int. Suppl. 2024;13(1):71–82. doi: 10.1016/j.kisu.2024.01.005.
- Couser W.G., Remuzzi G., Mendis S., Tonelli M. The contribution of chronic kidney disease to global health: a call for action. Kidney Int. 2011;80(12):1258–70. doi: 10.1038/ki.2011.190.
- Hu J., Ke R., Teixeira W. et al. Global, Regional, and National Burden of CKD due to Glomerulonephritis from 1990 to 2019: A Systematic Analysis from the Global Burden of Disease Study 2019. Clin. J. Am. Soc. Nephrol. 2023;18(1):60–71. doi: 10.2215/CJN.0000000000000017.
- Kebede M.A., Mengistu Y.T., Loge B.Y. et al. Determinants of Disease Progression in Autosomal Dominant Polycystic Kidney Disease. J. Pers. Med. 2024;14(9):936. doi: 10.3390/jpm14090936.
- Willey C.J., Blais J.D., Hall A.K. et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol. Dial. Transplant. 2017;32(8):1356–63. doi: 10.1093/ndt/gfw240.
- Rafique Z., Sadaf S., Batool S. et al. Morphological Spectrum of Glomerulonephritis in Medical Renal Biopsies: A Single-Center Study. Cureus. 2022;14(2):e22579. doi: 10.7759/cureus.22579.
- Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(2S):S1–239. doi: 10.1016/j.kint.2024.07.009.
- Bhutani G., Astor B.C., Mandelbrot D.A. et al. Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease. Kidney 360. 2024;2(2):312–24. doi: 10.34067/KID.0001182019.
Supplementary files
